If your doctor tells you your LDL is dangerously high, the reflexive response is fear — followed quickly by a prescription for statins. But the standard cholesterol panel leaves out information that fundamentally changes how you should interpret that number. LDL is not simply "bad cholesterol" clogging your arteries. It is a protein-based cargo carrier made by the liver, designed to deliver cholesterol to cells that need it to produce hormones, vitamin D, bile salts, and the structural material for cell membranes. Understanding what that carrier actually contains — and what type it is — matters far more than the total number on your lab report.
What LDL Actually Carries
LDL particles are not just filled with cholesterol. They also transport 45% of your body's circulating vitamin E, 76% of carotenoids like beta-carotene, coenzyme Q10 (a key antioxidant that supports heart muscle and mitochondria), and vitamin K. The presence of these critical nutrients inside LDL raises an obvious question: if LDL were simply a pathological substance, why would your body load it with protective compounds?
More striking still, over 50% of all heart attacks occur in people with normal LDL levels. That fact alone should prompt skepticism about using total LDL as the primary marker of cardiovascular risk.
Particle Size Is What Actually Matters
The number on a standard lipid panel measures total LDL by weight per volume. What it does not measure is particle size — and that distinction is critical. There are two main types of LDL particles:
- Small dense LDL: These particles are small enough to penetrate the arterial wall and contribute to plaque formation. They are the type associated with cardiovascular risk.
- Large buoyant LDL: These larger particles do not penetrate the arterial wall in the same way and are considered largely non-pathogenic.
A standard cholesterol test cannot distinguish between these two types. To find out which kind you have, you need an advanced lipid profile test. A related marker called apoB — which measures the total number of LDL particles rather than their size — can serve as an indirect indicator: a high apoB suggests a higher proportion of small dense particles, since more small particles fit into circulation than large ones.
Small dense LDL tends to rise in the presence of inflammation, insulin resistance, and excess refined carbohydrate intake. Large buoyant LDL, by contrast, is commonly seen in metabolically healthy individuals, including those following low-carbohydrate or ketogenic diets. A subset of these people — sometimes called lean mass hyper-responders — experience elevated total LDL on keto, but their elevation is almost entirely in the large buoyant fraction, and their triglycerides remain normal.
04:20
Diagram comparing small dense LDL particles versus large buoyant LDL particles inside an LDL cargo unit
Watch at 04:20 →
The Limits of Diet Research: A Closer Look at the PREDIMED Study
The most frequently cited evidence for dietary prevention of heart disease is the PREDIMED trial — a study of over 7,000 people in Spain, published in the New England Journal of Medicine, that claimed the Mediterranean diet reduced cardiovascular events by 30%. That figure is repeated constantly in medical advice and media coverage. It deserves a much harder look.
What Was Actually Compared
The Mediterranean diet group received free olive oil, free nuts, and dietary counseling. The control group was told to follow a low-fat diet — but didn't. Their actual fat intake came in at 37% of calories. The Mediterranean group consumed 41% fat. The real-world difference between the two groups was a 4-percentage-point difference in fat intake, with one group receiving more support and free food.
The Study Was Retracted
In 2018, the New England Journal of Medicine retracted the study after it emerged that 21% of participants had never been properly randomized — at one site, an entire group was assigned to the same diet rather than individuals being randomized. The paper was republished with reanalyzed data, but it could no longer claim to be a properly randomized controlled trial.
Relative Risk vs. Absolute Risk
The 30% figure is a relative risk reduction — a measurement that sounds dramatic but can be deeply misleading without context. Here is what it actually means in practice:
- In the control group, roughly 4 out of 100 people had a cardiovascular event over five years.
- In the Mediterranean diet group, roughly 3 out of 100 people had a cardiovascular event.
- That is a difference of one person per hundred — an absolute risk reduction of approximately 1%.
One fewer event per hundred people, over five years, comparing a group given free food and coaching to a group given advice they mostly ignored. That is the strongest dietary evidence we have for preventing heart disease.
It is also worth noting that the event reduction in PREDIMED was driven primarily by stroke, not heart attacks. The study produced no meaningful data showing reduced heart attack rates or heart attack deaths.
14:30
Two classrooms of 100 people illustrating the difference between relative risk and absolute risk reduction
Watch at 14:30 →
Correlation Is Not Causation — and LDL Is No Exception
Randomized controlled trials on LDL have never demonstrated that elevated LDL causes heart attacks or cardiovascular death. What exists is statistical association — and association is not causation. Owning a television is statistically associated with heart disease. Baldness is a recognized risk factor for cardiovascular events. No one prescribes Rogaine to prevent a heart attack, because the association reflects underlying factors, not direct causation.
In over 12 studies of elderly populations, higher LDL was associated with longer survival. Plaque in arteries is composed of 60 to 87% fibrous tissue and calcium. The cholesterol found in plaque largely originates from oxidized cholesterol released by dead white blood cells — not from dietary cholesterol traveling directly into arterial walls.
What You Should Know About Statins
Statins are prescribed based largely on total LDL numbers, without regard for particle size. Across 21 statin trials, the reported relative risk reduction for heart attacks was 29% — a number that follows the same pattern as PREDIMED. When converted to absolute risk, it falls to approximately 1.3%, meaning roughly 99 out of 100 people on statins experience no measurable benefit in terms of prevented heart attacks.
Beyond efficacy questions, statins work by blocking cholesterol production in the liver. Since cholesterol is the raw material for sex hormones, cortisol, vitamin D, and bile salts, reducing its production has downstream consequences:
- Depletion of coenzyme Q10, leading to muscle pain and fatigue
- Reduced testosterone and other sex hormones
- Impaired stress hormone production
- Lower vitamin D synthesis
- Reduced bile production, impairing absorption of fat-soluble vitamins
If you have been told your LDL is high, the most important next step is not to immediately accept a statin prescription. Request an advanced lipid profile to determine your particle size, check your apoB, and assess whether your elevated LDL is the small dense variety driven by metabolic dysfunction — or the large buoyant type that carries a very different risk profile. The number alone is not the story.
